<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337804</url>
  </required_header>
  <id_info>
    <org_study_id>18136</org_study_id>
    <secondary_id>P08050</secondary_id>
    <nct_id>NCT01337804</nct_id>
  </id_info>
  <brief_title>A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)</brief_title>
  <official_title>A Single Dose, Comparative, Open-label, Randomized, Crossover Bioequivalence Study of Omeprazole Administered as Zegerid® Powder for Oral Suspension 20 mg and Prilosec 40 mg Capsule in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the bioequivalence of omeprazole administered as either Zegerid® powder&#xD;
      for oral suspension 20 mg or as Prilosec 40 mg capsule to healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from 0 to infinity (AUC[0-∞])</measure>
    <time_frame>Up to 12 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 12 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Heartburn</condition>
  <arm_group>
    <arm_group_label>Zegerid-Prilosec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Zegerid in Period 1 and Prilosec in Period 2, with a 10- to 21-day washout between study drug administrations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prilosec-Zegerid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Prilosec in Period 1 and Zegerid in Period 2, with a 10- to 21-day washout between study drug administrations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole/sodium bicarbonate</intervention_name>
    <description>Single 20 mg dose of omeprazole/sodium bicarbonate powder for oral suspension</description>
    <arm_group_label>Prilosec-Zegerid</arm_group_label>
    <arm_group_label>Zegerid-Prilosec</arm_group_label>
    <other_name>Zegerid Powder for Oral Suspension</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole magnesium</intervention_name>
    <description>Single 40 mg capsule of omeprazole given orally</description>
    <arm_group_label>Prilosec-Zegerid</arm_group_label>
    <arm_group_label>Zegerid-Prilosec</arm_group_label>
    <other_name>Prilosec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is of non-Asian origin.&#xD;
&#xD;
          -  Female participants of reproductive potential must have a negative pregnancy test and&#xD;
             agree to use (and/or have their partner use) two acceptable methods of birth control&#xD;
             beginning at the screening visit, throughout the study, and until 2 weeks after the&#xD;
             last dose of study drug.&#xD;
&#xD;
          -  Participant has a Body Mass Index (BMI) ≤35 kg/m2 at the screening visit.&#xD;
&#xD;
          -  Participant is judged to be in good health.&#xD;
&#xD;
          -  Participant has no clinically significant abnormality on electrocardiogram (ECG).&#xD;
&#xD;
          -  Participant has been a nonsmoker and/or has not used nicotine or nicotine-containing&#xD;
             products for at least 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant is mentally or legally incapacitated, has significant emotional problems&#xD;
             at the time of screening visit or has a history of a clinically significant&#xD;
             psychiatric disorder over the last 5 to 10 years. Participants who have had&#xD;
             situational depression may be enrolled in the study at the discretion of the&#xD;
             investigator.&#xD;
&#xD;
          -  Participant has a history of any illness that, in the opinion of the study&#xD;
             investigator, might confound the results of the study or poses an additional risk to&#xD;
             the participant by their participation in the study.&#xD;
&#xD;
          -  Participant has taken any gastric antisecretory drugs (e.g., histamine receptor type-2&#xD;
             antagonists [H2RAs] or proton pump inhibitors [PPIs]), antacids, or any other&#xD;
             prescription or over- the-counter (OTC) medications within 14 days prior to Period 1&#xD;
             and during the trial.&#xD;
&#xD;
          -  Participant has been treated with any trial drug or therapy, or participated in a&#xD;
             clinical trial in the 30 days prior to Period 1.&#xD;
&#xD;
          -  Participant has any laboratory test result prior to dosing in Period 1 deviating from&#xD;
             the normal reference ranges established by the local laboratory by more than 20% that&#xD;
             the investigator judges to be of possible clinical significance.&#xD;
&#xD;
          -  Participant has an estimated creatinine clearance of ≤80 mL/min based on the&#xD;
             Cockcroft-Gault equation.&#xD;
&#xD;
          -  Participant has a history of stroke, chronic seizures, or major neurological disorder.&#xD;
&#xD;
          -  Participant has a history of clinically significant endocrine, gastrointestinal,&#xD;
             cardiovascular, hematological, hepatic, immunological, renal, respiratory, or&#xD;
             genitourinary abnormalities or diseases. Participants with a history of uncomplicated&#xD;
             kidney stones or childhood asthma may be enrolled in the study at the discretion of&#xD;
             the investigator.&#xD;
&#xD;
          -  Participant has a history of neoplastic disease.&#xD;
&#xD;
          -  Participant is a nursing mother.&#xD;
&#xD;
          -  Participant has any history or serologic evidence of hepatitis B or C with abnormal&#xD;
             liver function tests (except for benign, self-limited hepatitis A &gt;5 years prior to&#xD;
             randomization), hepatic or biliary tract disease, or a history of gastrointestinal&#xD;
             tract surgery.&#xD;
&#xD;
          -  Participant has an allergy or hypersensitivity to any component/excipient of the study&#xD;
             drugs, has a history of significant multiple and/or severe allergies (including latex&#xD;
             allergy), or has had an anaphylactic reaction or significant intolerability to&#xD;
             prescription or non-prescription drugs or food.&#xD;
&#xD;
          -  Participant is unable to refrain from or anticipates the use of any medication,&#xD;
             including prescription and non-prescription drugs or herbal remedies (such as St.&#xD;
             John's Wort [hypericum perforatum]) beginning approximately 2 weeks (or 5 half-lives)&#xD;
             prior to administration of the initial dose of study drug, throughout the study&#xD;
             (including washout intervals between treatment periods), until the telephone&#xD;
             follow-up. There may be certain medications that are permitted. Participants must be&#xD;
             explicitly warned of the potential risk of taking erythromycin, clarithromycin,&#xD;
             nefazodone, ketoconazole, itraconazole, cyclosporine, and human immunodeficiency virus&#xD;
             (HIV)protease inhibitors during the study.&#xD;
&#xD;
          -  Participant consumes excessive amounts of alcohol, defined as greater than 3 glasses&#xD;
             per day of alcoholic beverages (1 glass is approximately equivalent to: 10 ounces of&#xD;
             beer, 4 ounces of wine, or 1 ounce of distilled spirits).&#xD;
&#xD;
          -  Participant has consumed grapefruit juice, grapefruits and grapefruit products within&#xD;
             2 weeks prior to administration of the initial dose of study drug, and does not agree&#xD;
             to refrain from their consumption throughout the study (including the washout interval&#xD;
             between treatment periods) and until the telephone follow-up.&#xD;
&#xD;
          -  Participant consumes excessive amounts, defined as greater than 6 servings (1 serving&#xD;
             is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, chocolate, or&#xD;
             other caffeinated beverages per day.&#xD;
&#xD;
          -  Participant has had major surgery, donated or lost 1 unit of blood (approximately 500&#xD;
             mL) or participated in another investigational study within 30 days prior to Period 1.&#xD;
             The 4-week window will be derived from the date of the last study procedure (i.e.,&#xD;
             telephone follow-up) in the previous study to the screening visit of the current&#xD;
             study.&#xD;
&#xD;
          -  Participant is currently a regular user (including &quot;recreational use&quot;) of any illicit&#xD;
             drugs or has a history of drug (including alcohol) abuse within approximately 1 year.&#xD;
&#xD;
          -  There is any concern by the investigator regarding the safe participation of the&#xD;
             participant in the study or for any other reason; the investigator considers the&#xD;
             participant inappropriate for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>February 20, 2015</last_update_submitted>
  <last_update_submitted_qc>February 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

